Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review

Girolamo Ranieri, Marianna Pantaleo, Mariagrazia Piccinno, Maria Roncetti, Maddalena Mutinati, Ilaria Marech, Rosa Patruno, Annalisa Rizzo, Raffaele Luigi Sciorsci

Research output: Contribution to journalArticlepeer-review

Abstract

Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In particular, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and pet malignancies. A variety of small molecule inhibitors targeting specific tyrosine kinases (known as tyrosine kinase inhibitors or TKIs) have recently been approved, or are under investigation, for the treatment of human cancer. TKI application in animal cancer is however relatively recent. This review aims to illustrate the major aspects of tyrosine kinase dysfunctions, with special regard to human and animal cancer of the mammary gland, providing an update on the background of the anti-angiogenic and anti-neoplastic properties of TKIs in human and veterinary cancer.

Original languageEnglish
Pages (from-to)293-308
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume88
Issue number2
DOIs
Publication statusPublished - Nov 2013

Keywords

  • Angiogenesis
  • Bitch
  • Breast cancer
  • Comparative oncology
  • Pets
  • Queen
  • Tyrosine kinase inhibitors
  • Tyrosine kinase receptors
  • Women

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review'. Together they form a unique fingerprint.

Cite this